| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 128.69% | Morgan Stanley | $12 → $11 | Maintains | Overweight |
| 08/09/2023 | 149.48% | Morgan Stanley | $27 → $12 | Maintains | Overweight |
| 08/08/2023 | 253.43% | Deutsche Bank | $23 → $17 | Maintains | Buy |
| 08/08/2023 | 274.22% | RBC Capital | $20 → $18 | Maintains | Outperform |
| 08/08/2023 | 66.32% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
| 08/08/2023 | 128.69% | Baird | $18 → $11 | Maintains | Outperform |
| 08/08/2023 | 128.69% | Credit Suisse | $14 → $11 | Maintains | Neutral |
| 08/08/2023 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 05/23/2023 | 191.06% | Credit Suisse | $18 → $14 | Downgrades | Outperform → Neutral |
| 05/10/2023 | 170.27% | Goldman Sachs | $16 → $13 | Maintains | Neutral |
| 05/10/2023 | 461.33% | Morgan Stanley | $29 → $27 | Maintains | Overweight |
| 05/09/2023 | 315.8% | RBC Capital | $22 → $20 | Maintains | Outperform |
| 05/09/2023 | 170.27% | Goldman Sachs | $16 → $13 | Downgrades | Buy → Neutral |
| 05/09/2023 | 378.17% | Deutsche Bank | $25 → $23 | Maintains | Buy |
| 05/09/2023 | 274.22% | Credit Suisse | $23 → $18 | Maintains | Outperform |
| 02/24/2023 | 502.91% | Morgan Stanley | $32 → $29 | Maintains | Overweight |
| 02/23/2023 | 357.38% | Baird | $25 → $22 | Maintains | Outperform |
| 02/23/2023 | 378.17% | Credit Suisse | $26 → $23 | Maintains | Outperform |
| 02/23/2023 | 398.96% | Keybanc | $28 → $24 | Maintains | Overweight |
| 01/17/2023 | 232.64% | Goldman Sachs | $18 → $16 | Maintains | Buy |
| 01/05/2023 | 232.64% | UBS | $20 → $16 | Downgrades | Buy → Neutral |
| 12/14/2022 | 419.75% | Deutsche Bank | → $25 | Initiates Coverage On | → Buy |
| 12/07/2022 | 357.38% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 11/04/2022 | 274.22% | Goldman Sachs | $30 → $18 | Maintains | Buy |
| 11/04/2022 | 565.28% | Morgan Stanley | $35 → $32 | Maintains | Overweight |
| 11/03/2022 | 253.43% | B of A Securities | $32 → $17 | Downgrades | Buy → Neutral |
| 11/03/2022 | 440.54% | Credit Suisse | $34 → $26 | Maintains | Outperform |
| 11/03/2022 | 482.12% | Keybanc | $35 → $28 | Maintains | Overweight |
| 08/25/2022 | 606.86% | Credit Suisse | → $34 | Initiates Coverage On | → Outperform |
| 08/08/2022 | 627.65% | Morgan Stanley | $49 → $35 | Maintains | Overweight |
| 07/14/2022 | 627.65% | Goldman Sachs | $44 → $35 | Maintains | Buy |
| 05/09/2022 | 918.71% | Morgan Stanley | $54 → $49 | Maintains | Overweight |
| 05/06/2022 | 918.71% | Keybanc | $58 → $49 | Maintains | Overweight |
| 02/25/2022 | 1022.66% | Morgan Stanley | $59 → $54 | Maintains | Overweight |
| 08/12/2021 | 1188.98% | Morgan Stanley | $54 → $62 | Maintains | Overweight |
| 08/11/2021 | 1022.66% | Credit Suisse | $44 → $54 | Maintains | Outperform |
| 08/11/2021 | 1105.82% | Keybanc | $46 → $58 | Maintains | Overweight |
| 05/11/2021 | 814.76% | Credit Suisse | $42 → $44 | Maintains | Outperform |
| 03/04/2021 | 1022.66% | Morgan Stanley | $35 → $54 | Maintains | Overweight |
| 03/03/2021 | 773.18% | Credit Suisse | $34 → $42 | Maintains | Outperform |
| 03/03/2021 | 856.34% | Keybanc | $39 → $46 | Maintains | Overweight |
| 03/01/2021 | 606.86% | Credit Suisse | $31 → $34 | Maintains | Outperform |
| 02/10/2021 | 710.81% | Keybanc | $33 → $39 | Maintains | Overweight |
| 12/16/2020 | 586.07% | Keybanc | → $33 | Initiates Coverage On | → Overweight |
| 12/15/2020 | 627.65% | Morgan Stanley | → $35 | Initiates Coverage On | → Overweight |
| 12/15/2020 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 12/15/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/15/2020 | 544.49% | Stifel | → $31 | Initiates Coverage On | → Buy |
| 12/15/2020 | 544.49% | Baird | → $31 | Initiates Coverage On | → Outperform |
| 12/15/2020 | 690.02% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 12/14/2020 | 565.28% | UBS | → $32 | Initiates Coverage On | → Buy |
What is the target price for Maravai LifeSciences (MRVI)?
The latest price target for Maravai LifeSciences (NASDAQ: MRVI) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $11.00 expecting MRVI to rise to within 12 months (a possible 128.69% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Maravai LifeSciences (MRVI)?
The latest analyst rating for Maravai LifeSciences (NASDAQ: MRVI) was provided by Morgan Stanley, and Maravai LifeSciences maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Maravai LifeSciences (MRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Maravai LifeSciences (MRVI) correct?
While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a maintained with a price target of $12.00 to $11.00. The current price Maravai LifeSciences (MRVI) is trading at is $4.81, which is out of the analyst's predicted range.